公开(公告)号：US20230119720A1

公开(公告)日：2023-04-20

申请号：US18082793

申请日：2022-12-16

Applicant: GLYCOM A/S

Inventor： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: A method for treating metabolic disorders includes determining a treatment group comprising obese non-infant humans; formulating a composition comprising one or more synthetic non-fucosylated human milk oligosaccharides (HMOs) selected from lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and/or 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), and lacto-N-fucopentaose I (LNFP-I), that are effective for: increasing in the gastrointestinal microbiota of a non-infant human during a treatment period, the relative abundance of Bifidobacterium adolescentis and reducing a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage; and reducing the precursor condition in at least one non-infant human in the treatment group by providing the composition to the at least one non-infant human during the treatment period.

公开(公告)号：US10828313B2

公开(公告)日：2020-11-10

申请号：US15104794

申请日：2015-12-08

Applicant: GLYCOM A/S

Inventor： Emma Salomonsson ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

公开(公告)号：US20180169122A1

公开(公告)日：2018-06-21

申请号：US15897099

申请日：2018-02-14

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Salomonsson ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A23C9/20 ,  A23L33/21 ,  A61K31/7012 ,  A61K31/7004

CPC classification number: A61K31/702 ,  A23C9/206 ,  A23L33/21 ,  A23V2002/00 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A61K2300/00

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT).

公开(公告)号：US20170258820A1

公开(公告)日：2017-09-14

申请号：US15523379

申请日：2015-10-29

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Salomonsson ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A23L33/125 ,  A61K31/7016 ,  A23L33/00 ,  A61K31/7012 ,  A61K31/7004

CPC classification number: A61K31/702 ,  A23L33/125 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/7004 ,  A61K31/7012 ,  A61K31/7016 ,  A61K35/20 ,  A61P1/04 ,  A61K2300/00

Abstract: The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

公开(公告)号：US20160310514A1

公开(公告)日：2016-10-27

申请号：US15104794

申请日：2015-12-08

Applicant: GLYCOM A/S

Inventor： Emma Salomonsson ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnaes

IPC: A61K31/702 ,  A61K9/00

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

Abstract translation: 本发明涉及包含一种或多种人乳单糖和/或一种或多种用于降低代谢紊乱患者的肠通透性，内毒素血症和/或低度炎症的人乳寡糖的合成组合物。

公开(公告)号：US20160243138A1

公开(公告)日：2016-08-25

申请号：US15147112

申请日：2016-05-05

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Salomonsson ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7004

CPC classification number: A61K31/702 ,  A61K31/7004 ,  A61K2300/00

Abstract: The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for treating non-infectious diarrhoea.

Abstract translation: 本申请涉及含有一种或多种用于治疗非感染性腹泻的人乳单糖或寡糖的合成组合物。

公开(公告)号：US11833165B2

公开(公告)日：2023-12-05

申请号：US17341039

申请日：2021-06-07

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23L33/21 ,  A23C9/20

CPC classification number: A61K31/702 ,  A23C9/206 ,  A23L33/21 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23V2002/00 ,  A61K31/7004 ,  A61K2300/00 ,  A61K31/7012 ,  A61K2300/00 ,  A61K31/702 ,  A61K2300/00

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.

公开(公告)号：US11529364B2

公开(公告)日：2022-12-20

申请号：US17093337

申请日：2020-11-09

Applicant: GLYCOM A/S

Inventor： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

公开(公告)号：US20210308158A1

公开(公告)日：2021-10-07

申请号：US17341039

申请日：2021-06-07

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/702 ,  A61K31/7004 ,  A61K31/7012 ,  A61P1/04 ,  A23L33/21 ,  A23C9/20

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof

公开(公告)号：US11026959B2

公开(公告)日：2021-06-08

申请号：US15897099

申请日：2018-02-14

Applicant: Glycom A/S

Inventor： Thierry Hennet ,  Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC: A61K31/70 ,  A61K31/7012 ,  A61K31/7004 ,  A23L33/21 ,  A61K31/702 ,  A61P1/04 ,  A23C9/20

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2′-fucosyllactose (2′-FL) and lacto-N-neotetraose (LNnT).